Related Experiment Video
Updated: May 5, 2026

Colon Ascendens Stent Peritonitis CASP - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 19, 2010
Mast cell dipeptidyl peptidase I mediates survival from sepsis
Jon Mallen-St Clair1, Christine T N Pham, S Armando Villalta
1Department of Medicine and The Cardiovascular Research Institute, University of California, San Francisco, California 94143-0911, USA.
Abstract:
Sepsis is a common, life-threatening disease for which there is little treatment. The cysteine protease dipeptidyl peptidase I (DPPI) activates granule-associated serine proteases, several of which play important roles in host responses to bacterial infection. To examine DPPI's role in sepsis, we compared DPPI(-/-) and DPPI(+/+) mice using the cecal ligation and puncture (CLP) model of septic peritonitis, finding that DPPI(-/-) mice are far more likely to survive sepsis. Outcomes of CLP in mice lacking mast cell DPPI reveal that the absence of DPPI in mast cells, rather than in other cell types, is responsible for the survival advantage. Among several cytokines surveyed in peritoneal fluid and serum, IL-6 is highly and differentially expressed in DPPI(-/-) mice compared with DPPI(+/+) mice. Remarkably, deleting IL-6 expression in DPPI(-/-) mice eliminates the survival advantage. The increase in IL-6 in septic DPPI(-/-) mice, which appears to protect these mice from death, may be related to reduced DPPI-mediated activation of mast cell tryptase and other peptidases, which we show cleave IL-6 in vitro. These results indicate that mast cell DPPI harms the septic host and that DPPI is a novel potential therapeutic target for treatment of sepsis.
Insights
Mice lacking dipeptidyl peptidase I (DPPI) show increased survival from sepsis. This survival benefit is linked to mast cell DPPI and higher levels of interleukin-6 (IL-6), suggesting DPPI as a therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Pathology
Background:
- Sepsis is a life-threatening condition with limited therapeutic options.
- Dipeptidyl peptidase I (DPPI) activates proteases involved in host defense against bacterial infections.
Purpose of the Study:
- To investigate the role of DPPI in sepsis pathogenesis.
- To identify DPPI as a potential therapeutic target for sepsis treatment.
Main Methods:
- Comparison of DPPI knockout (DPPI(-/-)) and wild-type (DPPI(+/+)) mice in a cecal ligation and puncture (CLP) sepsis model.
- Assessment of survival rates and cytokine levels (IL-6) in peritoneal fluid and serum.
- In vitro experiments demonstrating IL-6 cleavage by DPPI-activated peptidases.
Main Results:
- DPPI(-/-) mice exhibited significantly higher survival rates following CLP compared to DPPI(+/+) mice.
- The survival advantage in DPPI(-/-) mice was attributed to the absence of DPPI specifically in mast cells.
- Septic DPPI(-/-) mice showed elevated levels of IL-6, and its deletion abolished the survival benefit.
- DPPI-activated peptidases were shown to cleave IL-6 in vitro.
Conclusions:
- Mast cell DPPI activity is detrimental to the host during sepsis.
- Elevated IL-6 levels in DPPI-deficient mice contribute to sepsis survival.
- DPPI represents a novel therapeutic target for sepsis treatment.
Related Concept Videos
Inflammation
Differentiation of Common Myeloid Progenitor Cells
Acute Inflammation II: Local and Systemic Effects
Acute Pancreatitis II: Pathophysiology

